Where does Gensight Biologics rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Gensight Biologics ranks #47,019 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Gensight Biologics hold?

Gensight Biologics holds 5 US utility patents granted between 2022 and 2025, spanning 7 technology areas.

What is Gensight Biologics's Innovation Score?

Gensight Biologics has an Innovation Score of 43.8 out of 100 (top 27% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Gensight Biologics focus on?

Gensight Biologics's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 4 patents, ranking #794 of 1,943 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Gensight Biologics's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Gensight Biologics.

What does claim depth mean for Gensight Biologics's patents?

Gensight Biologics's patents average 13.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Gensight Biologics patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Gensight Biologics

USPTO PatentsView assignee record - 5 granted patents across 7 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Gensight ranks #47,019 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 7 technology areas.

#47,019
of 49,997 US assignees by volume: Top 27%
by Innovation Score (43.8/100): 13.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R47019 · Foreign Corporation #47,019 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
BOTTOM-DECILE #47,019/49,997
PHOTO-FINISH Genial Light
CPC-NARROW A61N · 7 areas
INNOV-PAR 43.8/100
CLAIMS-RICH 13.8 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Genial Light Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Gensight’s 43.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (14%) Velocity 20.0 pts (46%) Breadth 9.4 pts (21%) Claim depth 8.3 pts (19%)

Qualcomm Incorporated · highest

85
Gensight Biologics · this assignee

44
3D Lighting… · lowest

7

What this shows Gensight's Innovation Score is 43.8/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Gensight?

Each dot is one of Gensight’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Gensight’s own 13.8 claims/patent is ABOVE the 10.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Gensight vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Gensight's grants concentrate

Gensight Biologics is a focused PatentsView assignee: 7 CPC subclasses with 80% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). By volume, Gensight sits between Genial Light Co., Ltd. and Geodigital International Inc..

Gensight's three-year grant acceleration

Gensight Biologics shows 4 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Genial Light

5
Genofocus

5
Genoplante-valor

5
Genovie AB

5
Gensun Institute…

5
Genus Industries

5
Geo-comm

5
Geodigital Intern…

5
Gensight Biologics ◀

5

What this shows Gensight holds 5 patents at rank #46,990, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Gensight

By rank, the assignees closest to #46,990 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Gensight's primary technology class.

Gensight's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Gensight Biologics patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	2	40.0%
2024	2	40.0%
2025partial year	1	20.0%

Which technologies does Gensight Biologics patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 4

G02B - Optical Elements, Systems OR Apparatus 3

G06V - Image OR Video Recognition OR Understanding 1

H04N - Pictorial Communication, e.g. Television 1

A61H - Physical Therapy Apparatus, e.g. Devices FOR Locating OR Stimulating Reflex Points IN THE BODY; Artificial RESPIRATION; MASSAGE; Bathing Devices FOR Special Therapeutic OR Hygienic Purposes OR Specific Parts OF THE Body 1

G02F - Optical Devices OR Arrangements FOR THE Control OF Light BY Modification OF THE Optical Properties OF THE Media OF THE Elements Involved THEREIN; Non-linear OPTICS; Frequency-changing OF LIGHT; Optical Logic ELEMENTS; Optical ANALOGUE/DIGITAL Converters 1

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Gensight Biologics's patent record in context - here's where to go next.

Gensight Biologics's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 80% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #47,019 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Gensight Biologics against Genial Light Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.